Table 1 Changes in CYP metabolic ratios during chemotherapy for breast cancer.

From: Influence of serum inflammatory cytokines on cytochrome P450 drug metabolising activity during breast cancer chemotherapy: a patient feasibility study

Enzyme

Phenotyping

n

Before chemo phenotype ratio*

After chemo phenotype ratio*

After chemo/before chemo ratio (90% CI)

p**

CYP2C9

losartan/ E-3174

8

1.54

1.74

1.79 (0.79–2.78)

0.55

CYP2C19

omeprazole/5-hydroxyomeprazole

9

2.27

3.00

1.02 (0.78–1.26)

0.82

CYP2D6

dextromethorphan/dextrorphan

8

0.65

0.68

1.26 (0.64–1.87)

1.00

CYP3A4

midazolam/α-hydroxymidazolam

9

2.18

2.29

1.08 (0.81–1.35)

0.91

  1. CI, confidence interval.
  2. *Mean ratios.
  3. **Statistical analysis was performed using Wilcoxon matched-pairs signed rank testing, and significance was determined as p < 0.05.
Back to article page